We conducted a prospective, randomized, single-center, open-label trial in patients with gout and men with inadequate renal uric acid excretion (defined as partial urate excretion < 5.5% and uric acid excretion ≤ 600 mg/day). /1.73m2). The researchers randomly assigned 196 participants to 25 mg per day of low-dose benzbromarone (LDBen) or 20 mg per day of low-dose febuxostat (LDFeb) for 12 weeks. All participants received daily urine alkalinization with oral sodium bicarbonate. The primary endpoint was a rate of achieving a serum urate (SU) target of <6 mg/dL.
Results showed that more participants in the LDBen group than in the LDFeb group achieved serum urate goals (61% vs. 32%, P<0.001). Adverse events, including gout recurrence and uremia, did not differ between groups, but more transaminases were elevated in the LDFeb group (LDBen 4% vs. LDFeb 15%, P=0.008).
Compared with LDFeb, LDBen has a superior uric acid-lowering effect and a similar safety profile in relatively young and healthy patients with renal insufficiency gout.
“The results suggest that low-dose benzbromarone may merit more consideration as a safe and effective therapy to achieve the serum uric acid target for gout control,” the authors wrote.
Read the paper to learn more: